环孢素A逆转白血病多药耐药的临床探讨

Clinical study on reversal of multi-drug resistance in relapsing or refractory acute leukemias by cyclosporin A(CsA)

目的探讨环孢素A(CsA)逆转复发难治性急性白血病(AL)多药耐药(MDR)的临床疗效。方法对45例复发难治性急性白血病患者进行P170检测,并对其中30例P170阳性患者随机分为治疗组(CsA+化疗)和对照组(单用化疗)进行逆转MDR的研究。结果P170在复发难治性急性白血病中有高表达(66.7%),治疗组总有效率(60.0%)明显高于对照组(26.7%),差异有显著性(P<0.05)。结论CsA能够逆转难治性白血病耐药性,在治疗复发难治性急性白血病方面具有良好的临床应用价值。

Objective To explore the clinical therapeutic effectiveness of reversal of multidrug resistance(MDR) by cyclosporin A(CsA).Methods The expression of P-170 was assayed in 45 cases of relapsing or refractory acute leukemias.The 30 cases who were P-170 positive were randomly divided into two groups: group for treatment (chemotherapy plus CsA) and control group (chemotherapy alone).Results The incidence of P-170 expression (66.7%) was higher in relapsing or refractory acute leukemias. The effective rates of treatment group and control group were 60.0% and 26.7% respectively(P<0.05).Conclusion CsA can reverse drug resistance of refractory acute myeloid leukemia,and was effective for reversal of MDR in relapsing or refractory acute leukemia.